Shanghai, October 16, 2020 – 3D Medicines announced that a new laboratory building for Translational Medicine Center came into service, and the R&D capabilities continued to grow. As the main engines, the Translational Medicine Center and the Clinical Development Center continue to drive the development of the company. The completion of Phase I construction, as well as the opening of the new laboratory building for the Translational Medicine Center will enhance the company’s R&D capabilities in next-generation immuno-oncology, the accelerated R&D progress of the products, the rapid expansion of the existing pipelines, and exploration in indication expansion, further contributing to the realization of our vision of "helping people with cancer live longer and better" and benefiting cancer patients worldwide.

The Translational Medicine Center boasts a highly experienced team with strong problem-solving skills and expertise in systematic researches including high-throughput drug screening, cell signaling pathway research and biomarker development. The Phase I laboratories are well-equipped with Hamilton automated workstation, Beckman flow cytometer, EnSpire and Molecular Devices microplate readers and hundreds of commercial cell lines, thus further supporting the process of early-stage R&D projects and the evaluation of new drug introduction. Also, the planning for the Phase II project has been completed, and the layout will be reinforced with targeted drug delivery system, personalized medicine R&D and micro-workshops for high-end biological products. Moreover, it is worth mentioning that the new laboratory building located near Simcere Innovation Center enables mutual support between the two companies, driving our Translational Medicine Research Center to expand its reach to all aspects of immuno-oncology.

The Translational Medicine Center of 3D Medicines has provided support to the R&D of KN035 and 3D185, both of which are currently in clinical trials. Meanwhile, the development of 3D011, a self-innovated product based on tumor biomarkers, multiple next-generation immuno-oncology novel drugs and biomarkers is steadily moving forward.

John Gong, M.D., Ph.D., Chairman and CEO of 3D Medicines commented:”3D Medicines is always committed to providing cancer patients across the globe with more effective, more accessible, and more convenient options of next-generation immuno-oncology drugs, and the opening of our new laboratory building of the Translational Medicine Center will provide solid support for realizing our vision sooner.”

Jeffrey Lin, Ph.D., Vice President and Director of the Translational Medicine Center of 3D Medicines, noted, “The opening of the new laboratory building of the Translational Medicine Center marks the accelerated progress of 3D Medicines in the R&D of next-generation immuno-oncology drugs. With the help of all our research staff, we hope that 3D Medicines will lead the innovation in the industry and develop more high-quality drugs, thus benefiting tumor patients worldwide.”

Virtual Tour

A workman must first sharpen his tools if he is to do his work well. Upon walking into the operation area of the laboratory, the research atmosphere of precision and rigor prevails. Every work station and device is neatly in place.

Operation Scene

The R&D of new drugs is considered as one of the most complicated mental activities of human beings. Only those with the most earnest heart and the most rigorous attitude can achieve ultimate success and contribute to the health of mankind.

Group photo of some researchers

About 3D Medicines

3D Medicines, Inc. is a biopharmaceutical company at the stage of late clinical development and early commercialization. Taking “help people with cancer live longer and better” as our concept, 3D Medicines aims at the future long-term survival of cancer patients and focuses on the development of differentiated next-generation immuno-oncology drugs, helping cancer patients to live with prolonged survival time and a better quality of life. 3D Medicines has established a pipeline with both innovative biological and small-molecule anti-cancer drugs, as well as a professional team capable of global development, registration and commercialization operation for new drugs.